Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference
26 Febbraio 2024 - 2:30PM
Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:
DRTS, DRTSW), the developer of the innovative alpha-radiation
cancer therapy Alpha DaRT™, today announced that management will
participate at the Barclays 26th Annual Global Healthcare
Conference on March 12th and 13th, 2024.
Event: |
Barclays 26th Annual Global Healthcare Conference |
Format: |
1-on-1 Meetings |
Date: |
March 12-13, 2024 |
Location: |
Miami, FL |
Please reach out to your Barclays representative to schedule a
one-on-one meeting.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company
that focuses on research, development, and potential
commercialization of the Alpha DaRT for the treatment of solid
tumors. The technology was initially developed by Prof. Itzhak
Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT™
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is
designed to enable highly potent and conformal alpha-irradiation of
solid tumors by intratumoral delivery of radium-224 impregnated
sources. When the radium decays, its short-lived daughters are
released from the sources and disperse while emitting high-energy
alpha particles with the goal of destroying the tumor. Since the
alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims
to mainly affect the tumor, and to spare the healthy tissue around
it.
Investor Relations Contact: IR@alphatau.com
Grafico Azioni Alpha Tau Medical (NASDAQ:DRTS)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Alpha Tau Medical (NASDAQ:DRTS)
Storico
Da Dic 2023 a Dic 2024